Efficacy of integrating cardiovascular risk management into cancer treatment protocols: a systematic review of current strategies and innovations
DOI:
https://doi.org/10.18203/2320-6012.ijrms20243003Keywords:
Cardiotoxicity, Cardiovascular diseases/prevention and control, Antineoplastic agents/adverse effects, Heart failure/prevention and control, Exercise therapyAbstract
Many of the anti-cancer agents, including anthracyclines, human epidermal growth factor receptor (HER2) inhibitors, and tyrosine kinase inhibitors are known to have cardiotoxic potential with potential consequences including heart failure, arrhythmias and myocardial ischemia. Therefore, the following systematic review questions have been developed to assess the effectiveness of incorporating cardiovascular risk in cancer management to counter these side effects. The literature search was extended on randomized control trials and meta-analysis in terms of cardioprotective strategies including global longitudinal strain (GLS), and ejection fraction (EF) both as guided therapy, and exercise prescription. Considering only patient characteristics, inclusion criteria included adult cancer patients receiving cardiotoxic treatments, whereas exclusion criteria excluded pediatric studies and non-randomized trials as well as trials without cardiovascular endpoints. The outcomes are evidence of lower cardiotoxicity with GLS-guided cardio-protection when compared to EF-based strategies, a decreased risk in left ventricular systolic dysfunction, and heart failure. The exercise interventions also have yielded favorable results in enhancing cardiovascular capacity and minimizing toxic consequences of chemotherapy on the cardiotoxicity level. Increasingly, eliminating and modifying cancer and oncology treatment strategies can help remedy disease outcomes; however, protocols for including these strategies in oncology plans have yet to be developed. Therefore, cardiovascular risk management conception in cancer treatment has to be regarded as crucial in avoidance of cardiotoxicity and improvement of quality of life and survival rate in oncological patients.
References
World Health Organization. Cancer. 2022. Available at: https://www.who.int/news-room/fact-sheets/ detail/cancer. Accessed on 09 August 2024.
Global Cancer Treatment. American Cancer Society. Available at: https://www.cancer.org/about-us/our-global-health-work/cancer-treatment.html. Accessed on 09 August 2024.
Liu F, Lan Q, Guo L. Enhancing cardiovascular disease risk management in childhood cancer survivors. Lancet Oncol. 2024;25(9):e400.
Bax C, Lotesoriere BJ, Sironi S, Capelli L. Review and comparison of cancer biomarker trends in urine as a basis for new diagnostic pathways. Cancers. 2019;11(9):1244.
Frères P, Bouznad N, Servais L, Josse C, Wenric S, Poncin A, et al. Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer. 2018;18:1-9.
Findlay SG, Gill JH, Plummer R, DeSantis C, Plummer C. Chronic cardiovascular toxicity in the older oncology patient population. J Geriatric Oncol. 2019;10(5):685-9.
Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1):e000472.
Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-90.
Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clinical Medicine Insights: Cardiology. 2019;13:1179546819866445.
Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care. 2021;10(8):947-59.
Mitchell JD, Lenihan DJ. Cardio-oncology: essentials for effective consultation. The Washington Manual Cardiology Subspecialty Consult. 2022;28.
Minasian LM, Davis M, Ky B. Cardiovascular effects of cancer therapy. In: Abeloff's Clinical Oncology. Elsevier. 2020;649-64.
Aggeli C, Dimitroglou Y, Raftopoulos L, Sarri G, Mavrogeni S, Wong J, et al. Cardiac masses: the role of cardiovascular imaging in the differential diagnosis. Diagnostics. 2020;10(12):1088.
Kaur H, Choi H, You YN, Rauch GM, Jensen CT, Hou P, et al. MR imaging for preoperative evaluation of primary rectal cancer: practical considerations. Radiographics. 2012;32(2):389-409.
Ramasamy I. Biochemical markers in acute coronary syndrome. Clinica Chimica Acta. 2011;412(15-16):1279-96.
Kuang Z, Kong M, Yan N, Ma X, Wu M, Li J. Precision Cardio-Oncology: Update on Omics-Based Diagnostic Methods. Curr Treatment Option Oncol. 2024;27.
Padegimas A, Carver JR. How to diagnose and manage patients with fluoropyrimidine-induced chest pain: a single center approach. Cardio Oncol. 2020;2(4):650-4.
Di Lisi D, Madonna R, Zito C, Bronte E, Badalamenti G, Parrella P, et al. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. Int J Cardiol. 2017;227:11-7.
Guo YF, Zhang XX, Yong LI, Duan HY, Jie BZ, Wu XS. Neuregulin-1 attenuates mitochondrial dysfunction in a rat model of heart failure. Chinese Med J. 2012;125(5):807-14.
Wang Y, Wei J, Zhang P, Zhang X, Wang Y, Chen W, et al. Neuregulin-1, a potential therapeutic target for cardiac repair. Front Pharmacol. 2022;13:945206.
Hassan SA, Palaskas N, Kim P, Iliescu C, Lopez-Mattei J, Mouhayar E, et al. Chemotherapeutic agents and the risk of ischemia and arterial thrombosis. Curr Atherosclerosis Rep. 2018;20:1-9.
Manolis AA, Manolis TA, Mikhailidis DP, Manolis AS. Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies–part 1. Exp Opinion Drug Safety. 2018;17(9):875-92.
Giudice V, Vecchione C, Selleri C. Cardiotoxicity of novel targeted hematological therapies. Life. 2020;10(12):344.
Alomar M, Fradley MG. Electrophysiology translational considerations in cardio-oncology: QT and beyond. J Cardiovasc Transl Res. 2020;13(3):390-401.
Allegra A, Alonci A, Russo S, Cannavò A, Penna G, D'Angelo A, et al. Cardiac involvement in patients with hematologic malignancies. J Investig Med. 2010;58(7):859-74.
Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduc Targeted Ther. 2023;8(1):262.
Alassadi S, Pisani MJ, Wheate NJ. A chemical perspective on the clinical use of platinum-based anticancer drugs. Dalton Transac. 2022;51(29):10835-46.